

Financial Results for 2nd Quarter of the Year Ending March 31, 2016 <Supplement>

As of October 30, 2015

Mitsubishi Tanabe Pharma Corporation



Mitsubishi Tanabe Pharma

Table of Contents

1	Summary of Financial Results for the 2nd Quarter of FY2015 Ending March 31, 2016 and Forecasts for FY2015	
	1. Summary of Financial Results for 2nd Quarter of FY2015	2
	2. Summary of Forecasts for FY2015 3. Dividends	...
2	Consolidated Financial Indicators for the 2nd Quarter of FY2015	
	1. Profit and Loss	3
	(1) Profit and Loss (2) Cost of Sales and SG&A Expenses	3
	(3) Non-operating Income and Loss (4) Extraordinary Income and Loss (5) Taxes	4
	(6) Sales of Main Products	5
	2. Financial Statement	6
	(1) Balance Sheet	6
	(2) Cash Flow Statement	7
	(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems (4) Depreciation Costs	8
	3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries	8
3	Forecasts for FY2015 Ending March 31, 2016	
	(1) Consolidated Forecasts of Profit and Loss (2) Forecasts of Cost of Sales and SG&A Expenses	9
	(3) Sales Forecasts for Main Products	10
	(4) Forecast for Investment in Property, Plant and Equipment and Information Systems	11
	(5) Forecasts for Depreciation Costs	11
4	Five-Year Financial Data	
	(1) Profit and Loss (2) Balance Sheet (3) Other Financial Data (4) Number of Employees	12
5	Quarterly Trend	
	(1) Profit and Loss	13
	(2) Sales of Main Products	14
6	State of New Product Development (as of October 30, 2015)	
	1. New Drugs	15
	2. Additional Indications	16
	3. Licensing-out	17
	4. Changes Since Previous Announcement on July 31, 2015	18
	(1) In-house Development (2) Licensing-out	18
	5. Additional Information for State of New Product Development	19
	(1) New Drugs	19
	(2) Additional Indications	19
	(3) Licensing-out	20
7	Others	
	1. Subsidiaries and Affiliated Companies	21
	(1) Number of Subsidiaries and Affiliated Companies (2) Consolidated Subsidiaries	
	(3) Affiliated Companies Accounted for by the Equity Method	21
	2. Status of Shareholders	22
	(1) Number of Outstanding Shares	
	(2) Status of Major Shareholders (3) Ownership and Distribution of Shares	
	(4) Trend of Dividend and Stock Price	22
	Reference	
	Major Ethical Drugs / News Releases	23

1 Summary of Financial Results for the 2nd Quarter of FY2015 Ending March 31, 2016 and Forecasts for FY2015

(Amounts less than ¥ 100 million are rounded.)

1. Summary of Financial Results for the 2nd Quarter of FY2015

				[Billion yen]
Net Sales	201.7	Y-on-Y	2.8	1.4 %
Domestic sales	150.9	Y-on-Y	(14.1)	(8.6 %)
Overseas sales	50.9	Y-on-Y	17.0	50.2 %

Net sales increased by 1.4%, or ¥2.8 billion, year-on-year, to ¥201.7 billion.

Domestic sales of ethical drugs decreased by 5.1%, year-on-year, to ¥147.3 billion due to the ending of the sales alliance of the plasma fractionation products in March 2015.

Royalty income, etc. is increased by 32.1%, year-on-year, to ¥36.8 billion due to the increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis and from INVOKANA and the fixed dose combination with metformin (IR), for the treatment of type2 diabetes mellitus, licensed to Janssen Pharmaceuticals.

				[Billion yen]
Operating Income	43.5	Y-on-Y	8.6	24.5 %

Operating income increased by 24.5%, or ¥8.6 billion, year-on-year, to ¥43.5 billion.

The cost of sales ratio improved by 3.0 percentage points, to 36.3% due to the ending of the sales alliance of the plasma fractionation products and the increase in royalty income. Gross profit increased by ¥7.9 billion, year-on-year, to ¥128.6 billion.

R&D expenses increased, on the other hand, sales promotion expenses decreased. Consequently, total SG&A expenses decreased by ¥0.7 billion, year-on-year, to ¥85.0 billion. R&D expenses were ¥33.3 billion, accounting for 16.5% of net sales.

				[Billion yen]
Ordinary Income	43.3	Y-on-Y	7.9	22.2 %
Net Income Attributable to Shareholders of the Company	29.1	Y-on-Y	(3.4)	(10.4 %)

Ordinary income was up 22.2%, or ¥7.9 billion, year-on-year, to ¥43.3 billion, and net income attributable to shareholders of the Company was down 10.4%, or ¥3.4 billion, year-on-year, to ¥29.1 billion.

Non-operating income/loss was down ¥0.7 billion, year-on-year, due to foreign exchange loss of ¥0.7 billion. Extraordinary income was ¥0.5 billion in compared with ¥13.6 billion in the same period of the previous fiscal year, due to gain on sales of property, plant and equipment, and gain on sales of investment in securities.

Extraordinary loss was ¥0.7 billion due to loss on impairment of fixed assets, in compared with ¥2.7 billion due to loss on liquidation of subsidiaries and affiliates and loss on impairment of fixed assets in the same period of the previous fiscal year.

2. Summary of Forecasts for FY2015

				[Billion yen]
Net Sales	418.0	Y-on-Y	2.9	0.7 %
Operating Income	82.0	Y-on-Y	14.9	22.1 %
Ordinary Income	81.0	Y-on-Y	13.3	19.7 %
Net Income Attributable to Shareholders of the Company	46.0	Y-on-Y	6.5	16.4 %

3. Dividends

	FY2015		FY2014	
	End of 1st Half	For the Year (Estimate)	End of 1st Half	For the Year
Dividends per Share (¥)	22	44	20	42
Dividends Payout Ratio	-	53.7%	-	59.6%
prior to amortization of goodwill	-	44.1%	-	47.6%

2 Consolidated Financial Indicators for the 2nd Quarter of FY2015

(Amounts less than ¥ 100 million are rounded.)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	1H FY2015	Y-on-Y			Comparison to previous forecasts			Notes [Y-on-Y comparison]
		1H FY2014	Increase (decrease)	Change %	Forecasts*	Increase (decrease)	Change %	
Net sales	201.7	198.9	2.8	1.4	191.5	10.2	5.3	See "Sales of Main Products" on page 5. Overseas sales ratio 1H FY2014: 17.0% 1H FY2015: 25.2% Average exchange rate 1H FY2014: 1US\$=¥103.61 1H FY2015: 1US\$ = ¥121.73
Domestic sales	150.9	165.0	(14.1)	(8.6)	144.3	6.6	4.5	
Overseas sales	50.9	33.9	17.0	50.2	47.2	3.7	7.8	
Cost of sales	73.2	78.2	(5.0)	(6.4)	70.5	2.7	3.8	Improved due to the ending of the sales alliance of the plasma fractionation products, increase of royalty income, etc.
Sales cost ratio	36.3%	39.3%			36.8%			
Gross operation profit	128.6	120.7	7.9	6.5	121.0	7.6	6.2	
SG&A expenses	85.0	85.8	(0.7)	(0.8)	93.0	(8.0)	(8.6)	
% of net sales	42.2%	43.1%			48.6%			
Operating income	43.5	35.0	8.6	24.5	28.0	15.5	55.4	
Ordinary income	43.3	35.5	7.9	22.2	28.0	15.3	54.7	
Extraordinary income and loss	(0.2)	10.9	(11.1)	-	-	(0.2)	-	
Net income attributable to shareholders of the Company	29.1	32.5	(3.4)	(10.4)	19.0	10.1	53.4	

(2) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	1H FY2015	Y-on-Y			Comparison to previous forecasts			Notes [Y-on-Y comparison]
		1H FY2014	Increase (decrease)	Change %	Forecasts*	Increase (decrease)	Change %	
Cost of sales	73.2	78.2	(5.0)	(6.4)	70.5	2.7	3.8	
% of net sales	36.3%	39.3%			36.8%			
SG&A expenses	85.0	85.8	(0.7)	(0.8)	93.0	(8.0)	(8.6)	
% of net sales	42.2%	43.1%			48.6%			
R&D expenses	33.3	31.9	1.3	4.2	39.5	(6.2)	(15.8)	
% of net sales	16.5%	16.1%			20.6%			
Except R&D expenses	51.8	53.8	(2.0)	(3.8)	53.5	(1.7)	(3.2)	
Labor cost	23.0	23.0	0.0	(0.1)	23.0	0.0	0.0	
Amortization of goodwill	5.3	5.4	(0.1)	(2.5)	5.3	0.0	(0.8)	
Others	23.5	25.4	(1.9)	(7.4)	25.2	(1.7)	(6.7)	
Total labor cost	38.6	39.8	(1.2)	(3.1)	38.2	0.4	1.1	

*: Published forecasts announced on May 8, 2015 in the financial results of FY2014

The Company announced "Revisions to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016" on September 30, 2015.

The revised forecasts for Q2 FY2015 are as follows; ¥200.0b of sales, up by ¥8.5b compared to the previous forecasts, ¥38.5b of operating income, up by ¥10.5b, ¥38.0b of ordinary income, up by ¥10.0b, and ¥25.5b of net income attributable to shareholders of the Company, up by ¥6.5b.

Please see page 9 for the revised forecasts for full year FY2015.

(3) Non-operating Income and Loss

[Billion yen]

	1H FY2015	1H FY2014	Increase (decrease)	Notes
Non-operating income	2.0	1.8	0.2	
Interest income	0.8	0.8	0.1	
Dividend income	0.6	0.4	0.2	
Others	0.5	0.6	(0.1)	
Non-operating expenses	2.2	1.3	0.9	
Interest expense	0.1	0.1	0.0	
Donations	0.4	0.3	0.1	
Foregin exchange loss	0.7	-	0.7	
Others	1.0	0.8	0.2	

(4) Extraordinary Income and Loss

[Billion yen]

	1H FY2015	1H FY2014	Increase (decrease)	Notes
Extraordinary income	0.5	13.6	(13.1)	
Gain on sales of property, plant and equipment	0.3	11.9	(11.7)	FY2015: Hiranomachi building No.1 FY2014: Gain on the sale of a vacant lot of the former Nihonbashi building
Gain on sales of investment in securities	0.2	1.1	(0.8)	
Gain on sales of shares of subsidiaries and affiliates	-	0.6	(0.6)	FY2014: Gain on the sales of shares of API Corporation and CMIC CMO ASHIKAGA
Extraordinary Loss	0.7	2.7	(2.0)	
Impairment loss	0.7	0.9	(0.2)	FY2015: Research building No.2 at Kashima FY2014: Toda dormitory, etc.
Loss on liquidation of subsidiaries and affiliates	-	1.4	(1.4)	FY2014: Loss on withdrawal of business of Mitsubishi Pharma (Guangzhou)
Loss on valuation of investment in securities	-	0.1	(0.1)	
Other	-	0.2	(0.2)	

(5) Taxes

[Billion yen]

	1H FY2015	1H FY2014	Increase (decrease)	Notes
Income before income taxes and minority interests	43.1	46.4	(3.2)	
Income taxes-current	13.0	16.1	(3.1)	
Income taxes-deferred	2.0	(1.5)	3.4	
Net Income	28.1	31.8	(3.6)	
Net income(loss) attributable to non-controlling interests	(1.0)	(0.8)	(0.2)	
Net Income attributable to shareholders of the Company	29.1	32.5	(3.4)	

(6) Sales of Main Products

[Billion yen]

	1H FY2015	Y-on-Y			Comparison to forecasts		
		1H FY2014	Increase (decrease)	Change %	Forecasts* ¹	Increase (decrease)	Change %
Ethical drugs	199.4	196.5	3.0	1.5	189.2	10.2	5.4
Ethical drugs domestic sales	147.3	155.2	(7.9)	(5.1)	140.8	6.5	4.6
Remicade	34.5	35.2	(0.7)	(2.1)	35.6	(1.1)	(3.1)
Talion	6.4	6.1	0.4	5.8	6.4	0.0	0.5
Ceredist	7.4	7.9	(0.5)	(6.6)	7.1	0.3	3.9
Maintate	6.9	7.2	(0.2)	(3.1)	6.6	0.3	5.0
Simponi	6.2	5.0	1.1	22.5	6.2	0.0	(0.5)
Tenelia(previous scheme) ^{*2}	3.7	2.7	1.1	40.2	4.5	(0.8)	(16.9)
Tenelia(new scheme) ^{*2}	2.9	Undisclosed	-	-	Undisclosed	-	-
Lexapro	4.4	3.4	1.0	28.5	4.1	0.3	7.0
Kremezin	4.8	5.4	(0.6)	(11.1)	4.8	0.0	0.4
Urso	4.4	5.1	(0.7)	(13.4)	4.6	(0.2)	(4.3)
Depas	3.7	4.1	(0.4)	(9.2)	3.4	0.3	9.3
Anplag	3.5	4.4	(0.9)	(20.4)	3.0	0.5	15.5
Radicut	3.4	3.8	(0.4)	(9.7)	2.9	0.5	18.2
BIKEN products [vaccine]	14.5	11.1	3.4	30.6	10.6	3.9	36.8
Influenza	2.8	0.9	1.9	212.7	0.6	2.2	362.3
Tetrabik	3.7	3.6	0.1	2.5	3.4	0.3	7.5
Varicella vaccine	3.3	1.9	1.4	73.0	2.3	1.0	44.8
Tanabe Seiyaku Hanbai products *3	6.6	6.4	0.2	2.6	6.9	(0.3)	(4.2)
Ethical drugs overseas sales	14.3	11.3	2.9	25.8	13.4	0.9	6.4
Herbesser	3.1	3.5	(0.4)	(10.4)	3.4	(0.3)	(8.7)
Argatroban (Novastan)	1.6	1.3	0.3	25.2	1.0	0.6	57.3
Tanatril	0.8	1.0	(0.2)	(18.5)	0.8	0.0	4.9
Contracted manufacturing products *4	1.1	2.1	(1.0)	(49.4)	1.1	0.0	(4.3)
Royalty income, etc.	36.8	27.9	8.9	32.1	33.9	2.9	8.5
Royalty from Gilenya	25.8	18.8	7.0	37.3	Undisclosed	-	-
Royalty from INVOKANA	9.9	Undisclosed	-	-	Undisclosed	-	-
OTC products	2.1	2.2	(0.1)	(3.8)	2.1	0.0	0.0
Total pharmaceuticals	201.7	198.9	2.8	1.4	191.5	10.2	5.3

*1: Published forecasts announced on May 8, 2015 in the financial results for FY2014.

*2: The sales scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company disclose total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*3: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*4: Active pharmaceutical ingredients and others ordered by other companies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of Q2 FY2015	Composition %	End of FY2014	Increase (decrease)	Notes
Total assets	920.9	100.0	929.3	(8.4)	
Current assets	611.0	66.3	603.6	7.3	
Cash and deposits	75.9	8.2	50.2	25.7	See Page 7, (2) Cash Flows Statement
Marketable securities	111.0	12.1	118.8	(7.8)	Increase in negotiable deposit, etc.
Notes and accounts receivable ^{*1}	129.1	14.0	130.3	(1.2)	
[Months/Revolution]	3.84		3.77	0.07	
Inventories	77.1	8.4	85.1	(8.0)	
Deposits	193.0	21.0	192.8	0.2	
Deferred income taxes	7.8	0.8	8.3	(0.6)	
Other	17.1	1.9	18.1	(1.1)	
Fixed assets	309.9	33.7	325.7	(15.7)	
Property, plant and equipment	90.2	9.8	92.5	(2.3)	Investment in plant and equipment, 4.6; depreciation, (3.6); disposal, sale, impairment and others, (2.3), etc.
Intangible fixed assets	109.2	11.9	116.9	(7.7)	Investment in information system, 0.5; depreciation, (0.8); amortization of goodwill of the merger, (5.0), etc.
Investment in securities	69.7	7.6	76.3	(6.6)	Increase of corporate bonds, etc.
Deferred income taxes	0.4	0.0	0.8	(0.3)	
Net defined benefit asset	18.2	2.0	15.7	2.4	
Other	22.1	2.4	23.4	(1.3)	
Total liabilities	103.2	11.2	128.9	(25.7)	
Current liabilities	78.5	8.5	105.4	(26.9)	
Notes and accounts payable ^{*2}	28.8	3.1	34.6	(5.8)	
Current maturities of long-term debt	0.1	0.0	0.1	0.0	
Accounts payable, other	15.9	1.7	25.4	(9.5)	
Income taxes payable	13.3	1.4	19.8	(6.4)	
Reserve for employees' bonuses	10.0	1.1	10.0	0.0	
Other	10.4	1.1	15.5	(5.1)	
Long-term liabilities	24.7	2.7	23.5	1.2	
Long-term debts	0.8	0.1	0.9	(0.1)	
Deferred income taxes	11.6	1.3	9.8	1.8	
Reserve for health management allowances for HIV compensation	1.7	0.2	1.7	-	
Reserve for health management allowances for SMON compensation	2.5	0.3	2.7	(0.2)	
Reserve for HCV litigation	1.9	0.2	2.0	(0.2)	
Net defined benefit liability	2.4	0.3	2.5	0.0	
Other	3.8	0.4	3.9	(0.1)	
Net assets	817.7	88.8	800.4	17.3	
Shareholders' equity	792.8	86.1	776.0	16.8	
Common stock	50.0	5.4	50.0	-	
Capital surplus	451.2	49.0	451.2	-	
Retained earnings	292.1	31.7	275.3	16.8	Net income attributable to shareholders of the Company, 29.1; payment for dividends, (12.3)
Treasury stock, at cost	(0.5)	(0.1)	(0.5)	0	
Accumulated other comprehensive loss	13.6	1.5	13.0	0.6	
Unrealized holding (losses) gains on securities	17.2	1.9	14.9	2.3	
Deferred (losses) gains on hedges	0.0	0.0	0.1	(0.1)	
Translation adjustments	(1.7)	(0.2)	0.1	(1.8)	
Remeasurements of defined benefit plans	(1.9)	(0.2)	(2.2)	0.3	
Non-controlling interests	11.3	1.2	11.5	(0.1)	

*1: Notes and accounts receivable = Bills + Accounts receivable

*2: Notes and account payable=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	1H FY2015	1H FY2014	Increase (decrease)
Cash and cash equivalents at beginning of year	73.3	85.0	(11.6)
Cash flows from operating activities	23.4	25.4	(1.9)
Income before income taxes and minority interests	43.1	46.4	(3.2)
Depreciation and amortization	4.4	4.5	(0.1)
Impairment loss	0.7	0.9	(0.2)
Amortization of goodwill	5.3	5.4	(0.1)
Decrease (increase) in net defined benefit asset	(2.4)	(2.1)	(0.3)
Interest and dividend income	(1.5)	(1.2)	(0.3)
Increase (decrease) in loss on liquidation of subsidiaries and affiliates	-	1.4	(1.4)
Loss (gain) on sales of shares of subsidiaries and affiliates	-	(0.6)	0.6
Loss (gain) on sales and disposal of fixed assets	(0.2)	(11.8)	11.7
Loss (gain) on sale of investment in securities	(0.2)	(1.1)	0.8
Decrease(increase) in notes and accounts receivable-trade	1.0	(3.3)	4.3
Decrease (increase) in inventories	5.0	(4.0)	9.0
Decrease(increase) in notes and accounts payable, trade	(5.7)	(1.7)	(4.0)
Increase(decrease) in accounts payable, other	(5.9)	(1.3)	(4.6)
Interest and dividend received	1.5	1.2	0.3
Income taxes paid	(19.6)	(9.7)	(9.9)
Other, net	(2.0)	2.4	(4.4)
Cash flows from investing activities	87.3	(7.3)	94.6
Purchase/sales etc. of marketable securities	60.8	(13.3)	74.1
Increase/decrease in time deposits	23.8	2.1	21.7
Increase in deposits	(0.2)	(10.3)	10.1
Purchase/sales of property, plant and equipment	(5.8)	6.2	(12.0)
Purchase of intangible fixed assets	(0.7)	(0.8)	0.2
Purchase/sales of investment in securities	6.2	1.3	4.9
Proceeds from sales of shares of subsidiaries and associates	-	7.6	(7.6)
Proceeds from company split	3.3	-	3.3
Other, net	(0.1)	(0.1)	0.0
Cash flows from financing activities	(10.9)	(11.4)	0.5
Increase (decrease) in short-term debt, net	-	(1.2)	1.2
Proceeds from share issuance to non-controlling shareholders	1.6	1.1	0.5
Cash dividends paid	(12.3)	(11.2)	(1.1)
Other, net	(0.2)	(0.1)	(0.1)
Effect of exchange rate change on cash and cash equivalents	(0.5)	0.7	(1.2)
Net increase (decrease) in cash and cash equivalents	99.3	7.4	92.0
Cash and cash equivalents at end of the year	172.7	92.3	80.3

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	1st half of FY2015	1st half of FY2014
Cash and time deposits	75.9	24.1
Time deposits maturing after three months	(1.5)	(2.9)
Short-term investments in marketable securities maturing within three months of acquisition	77.0	50.5
Cash equivalents included in short-term loans receivable*	1.3	0.6
Cash equivalents included in deposits	20.0	20.0
Cash and cash equivalents in the consolidated statements of cash flows	172.7	92.3

*: Short-term loans are included in "Others, Current Assets" on page 6.

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

	1H FY2015	1H FY2014	Increase (decrease)	FY2014
Investment in property, plant and equipment / occurring basis	4.6	6.2	(1.5)	15.7
Investment in information systems/ occurring basis	0.5	0.8	(0.3)	1.6

[Billion yen]

Major investment in property, plant and equipment in 1H FY2015		Major investment in development of information systems in 1H FY2015	
Mitsubishi Tanabe Pharma	1.4	Mitsubishi Tanabe Pharma	0.4
Mitsubishi Tanabe Pharma Factory	1.5		
[Restructuring of injection products facilities at Kashima plant]	[0.6]		
[Construction of new manufacturing facility at Yoshitomi plant]	[0.1]		

(4) Depreciation Costs

[Billion yen]

	1H FY2015	1H of FY2014	Increase (decrease)	FY2014
Property, plant and equipment	3.6	3.7	(0.1)	7.5
Intangible fixed assets	0.8	0.8	0.0	1.6

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

[Billion yen]

Companies	Mitsubishi Tanabe Pharma Factory Ltd.	Tanabe Seiyaku Hanbai Co., Ltd.	Mitsubishi Tanabe Pharma Korea Co., Ltd.	Medicago, Inc.	Tianjin Tanabe Seiyaku Co., Ltd.	P.T. Tanabe Indonesia	
Net sales	1H FY2015	14.8	6.6	2.4	0.2	2.5	0.8
	FY2014	39.4	13.6	4.4	1.1	4.5	2.3
	1H FY2014	19.1	6.4	2.1	0.9	2.1	1.6
Operating income	1H FY2015	1.8	(0.2)	0.2	(2.7)	0.2	(0.1)
	FY2014	3.6	(0.1)	0.2	(5.1)	0.5	0.1
	1H FY2014	1.6	(0.1)	0.2	(1.2)	0.2	0.2
Ordinary income	1H FY2015	1.9	(0.2)	0.2	(2.7)	0.1	(0.1)
	FY2014	3.6	(0.1)	0.3	(5.2)	0.5	0.1
	1H FY2014	1.7	(0.1)	0.2	(1.3)	0.3	0.2
Net income attributable to shareholders of the Company	1H FY2015	1.2	(0.1)	0.1	(2.7)	0.0	(0.1)
	FY2014	0.7	(0.1)	0.2	(5.3)	0.3	0.0
	1H FY2014	1.3	(0.1)	0.1	(1.4)	0.2	0.1
R&D expenses	1H FY2015	0.4	-	-	2.8	0.1	0.0
	FY2014	1.3	-	-	6.2	0.2	0.0
	1H FY2014	0.7	-	-	2.1	0.1	0.0
Depreciation of property, plant and equipment	1H FY2015	0.9	0.0	0.0	0.2	0.1	0.1
	FY2014	2.2	0.0	0.1	0.4	0.1	0.1
	1H FY2014	1.1	0.0	0.0	0.2	0.0	0.0
Total assets	End of 1H FY2015	44.7	5.5	3.5	34.5	5.9	2.8
	End of FY2014	48.2	6.0	3.7	35.6	6.1	3.1
	End of 1H FY2014	50.1	5.3	3.5	35.7	5.5	3.2
Net assets	End of 1H FY2015	37.8	0.1	2.8	24.0	3.8	1.4
	End of FY2014	36.9	0.3	3.0	24.2	3.9	1.7
	End of 1H FY2014	37.5	0.3	2.8	24.7	3.4	1.7
Number of employees	End of 1H FY2015	873	161	121	285	564	411
	End of FY2014	1,087	168	121	263	537	441
	End of 1H FY2014	1,099	173	123	226	468	463

Note: Prior to elimination of internal transaction

3 Forecasts for FY2015 Ending march 31, 2016

(Amounts less than ¥ 100 million are rounded)

(1) Consolidate Forecasts of Profit and Loss

[Billion yen]

	FY2015 revised forecasts ^{*1}	Comparison to previous forecasts			Comparison to previous fiscal year			Notes [Y-on-Y comparison]
		Previous forecasts ^{*2}	Increase (decrease)	Change %	FY2014 actual	Increase (decrease)	Change %	
Net sales	418.0	396.0	22.0	5.6	415.1	2.9	0.7	Overseas sales ratio FY2014: 18.8% FY2015 estimation : 27.4% Exchange rate planned: 1US\$=¥120
Domestic sales	303.4	301.5	1.9	0.6	337.2	(33.8)	(10.0)	
Overseas sales	114.6	94.5	20.1	21.3	77.9	36.7	47.1	
Cost of sales	150.0	147.0	3.0	2.0	169.6	(19.6)	(11.6)	Improved due to the ending of the sales alliance of the plasma fractionation products, increase of royalty
Sales cost ratio	35.9%	37.1%			40.9%			
Gross operatin profit	268.0	249.0	19.0	7.6	245.5	22.5	9.2	
SG & A expenses	186.0	181.5	4.5	2.5	178.4	7.6	4.3	
% of net sales	44.5%	45.8%			43.0%			
Operating income	82.0	67.5	14.5	21.5	67.1	14.9	22.1	
Ordinary income	81.0	67.0	14.0	20.9	67.7	13.3	19.7	
Extraordinary income and loss	(13.5)	(7.5)	(6.0)	-	(5.0)	(8.5)	-	
Net income attributable to shareholders of the Company	46.0	40.5	5.5	13.6	39.5	6.5	16.4	

(2) Forecasts of Cost of Sales and SG&A Expenses

[Billion yen]

	FY2015 revised forecasts ^{*1}	Comparison to previous forecasts			Comparison to previous fiscal year			Notes [Y-on-Y comparison]
		Previous forecasts ^{*2}	Increase (decrease)	Change %	FY2014 actual	Increase (decrease)	Change %	
Cost of sales	150.0	147.0	3.0	2.0	169.6	(19.6)	(11.6)	
Sales cost ratio	35.9%	37.1%			40.9%			
SG & A expenses	186.0	181.5	4.5	2.5	178.4	7.6	4.3	
% of Net sales	44.5%	45.8%			43.0%			
R&D expenses	76.0	74.0	2.0	2.7	69.6	6.4	9.2	
% of Net sales	18.2%	18.7%			16.8%			
Except R&D expenses	110.0	107.5	2.5	2.3	108.8	1.2	1.1	
Labor cost	47.0	46.0	1.0	2.2	46.8	0.2	0.5	
Amortization of goodwill	10.5	10.5	0.0	0.0	10.9	(0.4)	(3.8)	
Others	52.5	51.0	1.5	2.9	51.1	1.4	2.7	
Total labor cost	78.5	77.0	1.5	1.9	81.1	(2.6)	(3.2)	

*1: The Company announced "Revisions to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016" on September 30, 2015.

*2: Published forecasts announced on May 8, 2015 in the financial results of FY2014

(3) Sales Forecasts for Main Products

[Billion yen]

	FY2015 revised forecasts*1	Comparison to previous forecasts			Comparison to previous fiscal year		
		Previous forecasts*2	Increase (decrease)	Change %	FY2014 actual	Increase (decrease)	Change %
Ethical drugs	413.5	391.6	21.9	5.6	410.7	2.8	0.7
Ethical drugs domestic sales	296.6	294.6	2.0	0.7	323.9	(27.4)	(8.4)
Remicade	67.7	70.7	(3.0)	(4.3)	70.6	(3.0)	(4.2)
Talion	16.9	17.1	(0.2)	(1.4)	16.0	0.9	5.4
Ceredist	13.7	14.1	(0.4)	(3.0)	15.7	(2.0)	(12.7)
Maintate	13.2	13.2	0.0	0.2	14.1	(0.9)	(6.5)
Simponi	12.6	13.3	(0.7)	(5.5)	10.5	2.1	20.2
Tenelia (previous scheme)*3	3.7	9.6	(5.9)	(61.7)	6.2	(2.6)	(41.0)
Tenelia (new scheme)*3	9.9	Undisclosed	-	-	Undisclosed	-	-
Lexapro	10.4	10.5	(0.1)	(0.5)	8.0	2.5	30.9
Kremezin	9.1	9.3	(0.2)	(2.6)	10.5	(1.5)	(14.0)
Urso	8.4	8.8	(0.4)	(4.7)	10.0	(1.6)	(16.0)
Depas	7.0	6.8	0.2	2.7	8.1	(1.1)	(13.4)
Anplag	6.4	5.8	0.6	9.5	8.3	(1.9)	(23.4)
Radicut	6.2	5.4	0.8	15.1	7.4	(1.2)	(15.8)
BIKEN products [vaccine]	32.6	26.9	5.7	21.3	30.3	2.4	7.9
Influenza	11.2	7.9	3.3	42.0	7.4	3.8	51.9
Tetrabik	7.4	7.1	0.3	4.3	7.5	(0.1)	(1.6)
Varicella vaccine	6.1	4.4	1.7	39.3	7.2	(1.0)	(14.4)
Tanabe Seiyaku Hanbai products *4	14.0	14.4	(0.4)	(2.7)	13.6	0.4	3.0
Ethical drugs overseas sales	25.2	24.4	0.8	3.4	23.0	2.2	9.6
Herbesser	6.8	6.8	0.0	(0.2)	6.5	0.3	4.8
Argatroban (Novastan)	2.8	2.5	0.3	11.8	2.1	0.7	31.3
Tanatril	1.7	1.7	0.0	0.8	1.8	(0.1)	(6.5)
Contracted manufacturing products *5	2.1	2.4	(0.3)	(14.3)	3.4	(1.3)	(39.0)
Royalty income, etc.	89.6	70.2	19.4	27.7	60.4	29.3	48.5
Royalty from Gilenya	Undisclosed	Undisclosed	-	-	43.9	-	-
Royalty from INVOKANA	Undisclosed	Undisclosed	-	-	9.8	-	-
OTC products	4.1	4.0	0.1	2.7	4.0	0.1	2.8
Total pharmaceuticals	418.0	396.0	22.0	5.6	415.1	2.9	0.7

*1: The Company announced "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016" on September 30, 2015.

*2: Published forecasts announced on May 8, 2015 in the financial results for FY2014.

*3: The sales scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company disclose total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*4: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*5: Active pharmaceutical ingredients and others ordered by outside companies.

(4) Forecasts of Investment for Property, Plant and Equipment and Information Systems

[Billion yen]

	FY2015 forecasts	FY2014 actual	Increase (decrease)	Change %
Investment in property, plant and equipment/occurring basis	11.1	15.7	(4.6)	(29.5)
Investment for information systems/occurring basis	1.6	1.6	0.0	0.9

[Billion yen]

Major investment in property, plant and equipment in FY2015		Major investment for information systems in FY2015	
Facilities & equipment for R&D	7.4	R&D related systems	0.7
[Construction of new manufacturing facility at Yoshitomi plant]	[1.7]	Production related system	0.2
[Restructuring of injection products facilities at Kashima plant]	[1.6]	Others	0.7
Production facilities	3.2		
Others	0.4		

(5) Forecasts for Depreciation Costs

[Billion yen]

	FY2015 forecasts	FY2014 actual	Increase (decrease)	Change %
Property, plant and equipment	7.3	7.5	(0.2)	(2.4)
Intangible fixed assets	1.5	1.6	(0.1)	(3.3)

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2011	FY2012	FY2013	FY2014	1H FY2015	Forecast for FY2015
Net sales	407.2	419.2	412.7	415.1	201.7	418.0
Cost of sales	152.3	166.4	169.4	169.6	73.2	150.0
Gross operation profit	254.9	252.8	243.3	245.5	128.6	268.0
SG&A expenses	185.8	183.8	184.2	178.4	85.0	186.0
R&D expenses	70.2	66.5	70.4	69.6	33.3	76.0
Operating income	69.0	69.0	59.1	67.1	43.5	82.0
Ordinary income	68.8	69.4	61.9	67.7	43.3	81.0
Extraordinary income	1.2	4.2	15.3	13.7	0.5	(13.5)
Extraordinary loss	6.1	5.9	4.8	18.6	0.7	
Net income attributable to shareholders of the Company	39.0	41.9	45.4	39.5	29.1	46.0

(2) Balance Sheet

[Billion yen]

	End of FY2011	End of FY2012	End of FY2013	End of FY2014	End of 1H FY2015
Total assets	819.9	866.8	886.5	929.3	920.9
Current assets	419.7	476.7	540.5	603.6	611.0
Fixed assets	400.3	390.1	346.0	325.7	309.9
Total liabilities	98.4	113.9	108.6	128.9	103.2
Current liabilities	69.6	86.1	81.8	105.4	78.5
Fixed liabilities	28.9	27.7	26.8	23.5	24.7
Net assets	721.5	752.9	777.8	800.4	817.7

(3) Other Financial Data

[Billion yen]

	FY2011	FY2012	FY2013	FY2014	1H FY2015	Forecast for FY2015
Cash flows from operating activities	37.2	60.6	69.9	68.2	23.4	-
Cash flows from investing activities	(63.2)	(35.0)	(24.3)	(59.8)	87.3	-
Cash flows from financing activities	(17.2)	(23.7)	(21.1)	(21.9)	(10.9)	-
Investments in property, plant and equipment	7.1	9.2	12.6	15.7	4.6	11.1
Investments for development of information systems	1.2	2.2	2.1	1.6	0.5	1.6
Depreciation costs	12.5	8.4	9.2	9.0	4.4	8.8
Equity ratio (%)	87.3	86.3	86.4	84.9	87.6	-
ROE (%)	5.5	5.7	6.0	5.1	7.3	-
Net income per share (¥)	69.54	74.67	80.92	70.41	51.96	82.00
Net assets per share (¥)	1,275.85	1,333.22	1,365.52	1,406.41	1,437.45	-

(4) Number of Employees

	End of FY2011	End of FY2012	End of FY2013	End of FY2014	End of 1H FY2015	Forecast for end of FY2015
Consolidated	9,180	8,835	9,065	8,457	8,212	8,202
Non-consolidated	4,826	4,850	4,867	4,844	4,819	4,752

5 Quarterly Trend

(1) Profit and Loss

[Billion yen]

	FY2014					FY2015			
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full year Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	2H forecasts	Full year forecasts*
Net sales	94.6 22.8%	104.3 25.1%	120.9 29.1%	95.3 23.0%	415.1 100.0%	98.5 23.6%	103.2 24.7%	216.3 51.7%	418.0 100.0%
Domestic	79.8 23.7%	85.3 25.3%	98.6 29.2%	73.6 21.8%	337.2 100.0%	76.3 25.1%	74.6 24.6%	152.5 50.3%	303.4 100.0%
Overseas	14.8 19.0%	19.1 24.5%	22.3 28.7%	21.7 27.9%	77.9 100.0%	22.2 19.4%	28.6 25.0%	63.8 55.6%	114.6 100.0%
Cost of sales	39.2	39.0	49.8	41.6	169.6	35.5	37.6	76.8	150.0
Sales cost ratio	41.4%	37.4%	41.2%	43.6%	40.9%	36.1%	36.5%	35.5%	35.9%
Gross profit	55.4 22.6%	65.3 26.6%	71.0 28.9%	53.8 21.9%	245.5 100.0%	63.0 23.5%	65.6 24.5%	139.4 52.0%	268.0 100.0%
SG&A expenses	41.7 23.4%	44.1 24.7%	42.4 23.8%	50.2 28.2%	178.4 100.0%	40.2 21.6%	44.8 24.1%	101.0 54.3%	186.0 100.0%
R&D expenses	16.3 23.5%	15.6 22.4%	16.2 23.2%	21.5 30.9%	69.6 100.0%	15.5 20.3%	17.8 23.4%	42.7 56.2%	76.0 100.0%
Non-R&D expenses	25.3 23.3%	28.5 26.2%	26.3 24.1%	28.7 26.4%	108.8 100.0%	24.8 22.5%	27.0 24.6%	58.2 52.9%	110.0 100.0%
Labor costs	11.1 23.8%	11.9 25.5%	11.8 25.2%	12.0 25.6%	46.8 100.0%	11.2 23.8%	11.8 25.1%	24.0 51.0%	47.0 100.0%
Amortization of goodwill	2.7 24.7%	2.7 24.7%	2.7 24.7%	2.8 25.8%	10.9 100.0%	2.6 25.1%	2.6 25.0%	5.2 49.9%	10.5 100.0%
Others	11.5 22.6%	13.9 27.1%	11.8 23.1%	13.9 27.2%	51.1 100.0%	10.9 20.8%	12.6 24.0%	29.0 55.2%	52.5 100.0%
Operating income	13.7 20.4%	21.3 31.7%	28.6 42.7%	3.5 5.3%	67.1 100.0%	22.7 27.7%	20.8 25.3%	38.5 46.9%	82.0 100.0%
Ordinary income	14.6 21.5%	20.9 30.9%	28.6 42.3%	3.6 5.3%	67.7 100.0%	22.6 28.0%	20.7 25.5%	37.7 46.5%	81.0 100.0%
Net income attributable to shareholders of the Company	9.6 24.3%	22.9 58.1%	15.8 39.9%	(8.8) (22.3%)	39.5 100.0%	14.9 32.4%	14.3 31.0%	16.9 36.6%	46.0 100.0%

The each figure (excluding "cost of sales") in the lower displays the progress rate.

*: Revised forecasts announced in "Revisions to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016" on September 30, 2015.

(2) Sales of Main Products

[Billion yen]

	FY2014					FY2015			
	Q1	Q2	Q3	Q4	Full year	Q1	Q2	1st half	Full year
	Apr. to Jun.	Jul. to Sep.	Oct. to Dec.	Jan. to Mar.	actual	Apr. to Jun.	Jul. to Sep.	forecasts	forecasts ^{*1}
Ethical drugs	93.2	103.3	119.8	94.4	410.7	97.2	102.2	214.1	413.5
	22.7%	25.1%	29.2%	23.0%	100.0%	23.5%	24.7%	51.8%	100.0%
Ethical drugs domestic sales	77.5	77.7	96.8	71.9	323.9	74.3	73.1	149.2	296.6
	23.9%	24.0%	29.9%	22.2%	100.0%	25.0%	24.6%	50.3%	100.0%
Remicade	17.3	17.9	19.3	16.1	70.6	16.9	17.6	33.2	67.7
	24.6%	25.3%	27.3%	22.8%	100.0%	24.9%	26.1%	49.0%	100.0%
Talion	3.3	2.8	4.3	5.7	16.0	3.6	2.9	10.4	16.9
	20.3%	17.7%	26.6%	35.4%	100.0%	21.1%	17.0%	61.9%	100.0%
Ceredist	4.1	3.8	4.4	3.4	15.7	3.9	3.5	6.3	13.7
	26.4%	24.0%	27.9%	21.7%	100.0%	28.4%	25.5%	46.1%	100.0%
Maintate	3.8	3.4	3.8	3.2	14.1	3.7	3.2	6.3	13.2
	26.7%	23.9%	26.8%	22.6%	100.0%	27.9%	24.5%	47.6%	100.0%
Simponi	2.5	2.6	2.9	2.5	10.5	3.0	3.2	6.4	12.6
	23.5%	24.6%	27.9%	23.9%	100.0%	24.0%	25.1%	50.9%	100.0%
Tenelia (previous scheme) ^{*2}	1.1	1.6	1.9	1.7	6.2	2.0	1.7	(0.1)	3.7
	17.9%	24.9%	30.6%	26.5%	100.0%	55.4%	46.3%	(1.7%)	100.0%
Tenelia (new scheme) ^{*2}	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	7.0	9.9
	-	-	-	-	-	-	-	70.3%	100.0%
Lexapro	1.7	1.7	2.7	1.8	8.0	2.1	2.2	6.1	10.4
	21.1%	21.7%	34.3%	22.9%	100.0%	20.5%	21.5%	58.0%	100.0%
Kremezin	2.8	2.6	2.8	2.3	10.5	2.5	2.3	4.2	9.1
	26.6%	24.9%	26.8%	21.8%	100.0%	27.8%	25.4%	46.8%	100.0%
Urso	2.7	2.4	2.7	2.2	10.0	2.4	2.0	4.0	8.4
	26.7%	24.2%	27.0%	22.1%	100.0%	28.3%	24.2%	47.5%	100.0%
Depas	2.1	2.0	2.2	1.8	8.1	1.9	1.8	3.3	7.0
	25.9%	24.9%	27.1%	22.2%	100.0%	27.8%	25.4%	46.8%	100.0%
Anplag	2.4	2.0	2.2	1.7	8.3	1.9	1.6	2.9	6.4
	28.7%	23.9%	27.0%	20.5%	100.0%	30.1%	24.4%	45.5%	100.0%
Radicut	2.0	1.8	2.1	1.5	7.4	1.7	1.8	2.8	6.2
	26.7%	24.7%	28.3%	20.3%	100.0%	26.7%	28.5%	44.8%	100.0%
BIKEN products [vaccines]	4.9	6.2	14.8	4.4	30.3	6.3	8.2	18.1	32.6
	16.2%	20.4%	48.8%	14.5%	100.0%	19.3%	25.1%	55.6%	100.0%
Influenza	(0.1)	0.9	7.3	(0.8)	7.4	0.0	2.8	8.4	11.2
	(0.7%)	12.7%	99.3%	(11.3%)	100.0%	(0.3%)	25.0%	75.3%	100.0%
Tetrabik	1.8	1.8	2.1	1.8	7.5	1.9	1.7	3.8	7.4
	23.6%	23.7%	28.2%	24.4%	100.0%	26.1%	23.3%	50.7%	100.0%
Varicella vaccine	0.6	1.3	3.5	1.7	7.2	1.8	1.5	2.8	6.1
	8.7%	18.2%	48.8%	24.3%	100.0%	29.2%	25.2%	45.7%	100.0%
Tanabe Seiyaku Hanbai products ^{*3}	3.4	3.1	3.9	3.3	13.6	3.4	3.2	7.4	14.0
	24.8%	22.5%	28.6%	24.0%	100.0%	24.3%	22.8%	52.8%	100.0%
Ethical drugs overseas sales	5.3	6.0	5.5	6.2	23.0	6.2	8.1	11.0	25.2
	23.0%	26.3%	23.7%	27.1%	100.0%	24.5%	32.0%	43.5%	100.0%
Herbesser	1.6	1.9	1.4	1.6	6.5	1.5	1.6	3.7	6.8
	24.4%	29.1%	22.3%	24.2%	100.0%	22.1%	23.6%	54.2%	100.0%
Argatroban (Novastan)	0.7	0.6	0.5	0.4	2.1	0.5	1.1	1.2	2.8
	32.5%	26.5%	22.9%	18.1%	100.0%	17.0%	39.3%	43.7%	100.0%
Tanatril	0.5	0.6	0.4	0.4	1.8	0.5	0.4	0.9	1.7
	24.7%	31.4%	21.8%	22.1%	100.0%	26.6%	22.4%	51.0%	100.0%
Contracted manufacturing products ^{*4}	0.9	1.2	0.5	0.8	3.4	0.6	0.5	1.0	2.1
	27.0%	34.6%	15.1%	23.2%	100.0%	27.6%	23.6%	48.8%	100.0%
Royalty income, etc.	9.5	18.4	17.0	15.5	60.4	16.2	20.6	52.9	89.6
	15.7%	30.4%	28.2%	25.7%	100.0%	18.1%	23.0%	59.0%	100.0%
Royalty from Gilenya	7.7	11.1	13.7	11.4	43.9	11.2	14.6	Undisclosed	Undisclosed
	17.6%	25.3%	31.1%	26.0%	100.0%	-	-	-	-
Royalty from INVOKANA	Undisclosed	Undisclosed	Undisclosed	3.6	9.8	4.6	5.4	Undisclosed	Undisclosed
	-	-	-	37.3%	100.0%	-	-	-	-
OTC products	1.2	1.0	1.0	0.8	4.0	1.2	0.9	2.0	4.1
	30.4%	24.2%	24.9%	20.4%	100.0%	28.4%	22.7%	48.9%	100.0%
Total sales	94.6	104.3	120.9	95.3	415.1	98.5	103.2	216.3	418.0
	22.8%	25.1%	29.1%	23.0%	100.0%	23.6%	24.7%	51.7%	100.0%

The each figure in the lower displays the progress rate.

*1: The Company announced "Revision to Consolidated Financial Forecasts for Fiscal Year Ending March 31, 2016" on September 30, 2015.

*2: The scheme of Tenelia was changed from co-marketing by the Company and Daiichi Sankyo to solo marketing by Daiichi Sankyo from October 1, 2015. Co-promotion by the Company and Daiichi Sankyo is continued. According to the change, the Company disclose total of turnover to Daiichi Sankyo and promotion fee from Daiichi Sankyo as sales amount of Tenelia (new scheme).

*3: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*4: Active pharmaceutical ingredients and others ordered by other companies.

6 State of New Product Development (As of October 30, 2015)

1. New Drugs

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
TA-650 (infiximab)	Anti-human TNF α monoclonal antibody (Crohn's disease, ulcerative colitis, pediatric Crohn's disease, pediatric ulcerative colitis)	Taiwan	Filed (Sep., 2013)	US:Janssen Biotech
TA-7284 (canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Taiwan	Filed (Mar., 2015)	In-house
MP-513 (teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Indonesia	Filed (Apr., 2015)	In-house
		Europe	Phase 2	
		US	Phase 1	
MCI-186 (edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis [*])	Korea	Filed (Jun., 2015)	In-house
MT-2412 (teneligliptin, canagliflozin)	Fixed-dose combination of DPP-4 inhibitor and SGLT2 inhibitor (Type 2 diabetes mellitus)	Japan	Phase 3	In-house
MP-214 (cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Japan,Asia	Phase 2b/3	Hungary: Gedeon Richter
MT-4666 (encenicline)	α 7nACh receptor agonist (Dementia of Alzheimer's type)	Japan	Phase 2	US: FORUM Pharmaceuticals
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 2	In-house
		Japan	Phase 2	
		US	Phase 1	
MT-1303 (amiselimod)	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 2	In-house
	(Psoriasis)	Europe	Phase 2	
	(Crohn's disease)	Japan,Europe	Phase 2	
	(Inflammatory diseases, autoimmune diseases)	Japan,Europe, US	Phase 1	
MT-2301	Haemophilus influenza type b (Hib) vaccine (Prophylaxis of pediatric Hib infection)	Japan	Phase 2	US: Nuron Biotech
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of seasonal influenza)	US, Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Canada	Phase 1	In-house
GB-1057 (recombinant human serum albumin)	Blood and blood forming organs	US	Phase 1	In-house
MP-124	Nervous system	US	Phase 1	In-house
MP-157	Cardiovascular system	Europe	Phase 1	In-house
MT-0814	Ophthalmologicals	Japan	Phase 1	In-house
MT-8554	Nervous system etc.	Europe	Phase 1	In-house

*Orphan drug designated

2. Additional Indications

Product name (Generic name)	Category (Indications)	Region	Stage	Origin	Notes
Remicade (infliximab)	Anti-human TNF α monoclonal antibody (Refractory Kawasaki disease*)	Japan	sNDA filed (May, 2015)	US:Janssen Biotech	
	(Psoriasis: increased dose)		sNDA filed (Jul., 2015)		
	(Pediatric Crohn's disease)		Phase 3		
	(Pediatric ulcerative colitis)		Phase 3		
Tribik (adsorbed diphtheria-purified pertussis-tetanus combined vaccine)	Vaccine (Prophylaxis of pertussis, diphtheria, and tetanus; Stage 2 vaccination)	Japan	sNDA filed (Apr., 2015)	Japan:The Research Foundation for Microbial Diseases of Osaka University	Co-developed with The Research Foundation for Microbial Diseases of Osaka University
Telavic (telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [combination with Feron])	Japan	Phase 3	US:Vertex Pharmaceutic als	
Imusera (fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	In-house	Co-developed with Novartis Pharma in Japan, licensed to Novartis overseas
Canaglu (canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Global clinical trial	Phase 3	In-house	Sponsor: Janssen Research & Development, LLC

*Orphan drug designated

3. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee (Notes)
TA-7284 (canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus / fixed dose combination with metformin, XR)	US	Phase 3	US: Janssen Pharmaceuticals, Inc
	(Diabetic nephropathy)	Global clinical trial	Phase 3	
	(Type 1 Diabetes Mellitus)	US, Canada	Phase 2	
	(Obesity / co-administration with phentermine)	US	Phase 2	
FTY720 (fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	Switzerland: Novartis (Co-developed with Novartis Pharma in Japan)
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	US: Minerva Neurosciences
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Japan: Maruho
MCC-847 (masilukast)	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism in hemodialysis patients)	Japan	Phase 2	Japan: Kyowa Hakko Kirin
Wf-516	Multiple mechanisms on several receptors* (Depression)	Europe	Phase 2	US: Minerva Neurosciences
Y-803	Bromodomain inhibitor (Cancer)	Europe, Canada	Phase 2	US: Merck
sTU-199 (tenatoprazole)	Alimentary tract and metabolism	Europe	Phase 1	France: Negma/Sidem

*SSRI, 5-HT1A, dopamine transporter, and alpha-1A and B

4. Changes Since Previous Announcement on July 31, 2015

(1) In-house Development

Development code/ product name (Generic name)	Category (Indications)	Region	As of July 31, 2015	As of October 30, 2015
Remicade (infliximab)	Anti-human TNF α monoclonal antibody (Entero-, neuro-, and vasculo-Behcet's diseases ^{*1})	Japan	sNDA filed (Oct., 2014)	Approved (Aug., 2015)
MT-4666 (encenicline)	α 7nACh receptor agonist (Dementia of Alzheimer's type)	Japan	Phase 3	Phase 2 ^{*2}

*1 Orphan drug designated

*2 Due to the discontinuation of global phase3 clinical trial program in Japan

(2) Licensing-out

Development code	Category (Indications)	Region	As of July 31, 2015	As of October 30, 2015
TA-8995	CETP inhibitor (Dyslipidemia)	Europe	Phase 2	Deleted *

*Due to the transfer of patent and know-how to Amgen/Dezima

5. Additional Information for State of New Product Development (As of October 30, 2015)

(1) New Drugs

Development code (Generic name)	Information
TA-650 (infliximab)	TA-650 is an anti-human TNF α monoclonal antibody. In Japan, it was launched under the brand name of Remicade® in 2002.
TA-7284 (canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. It was launched in Japan for the treatment of type2 diabetes mellitus in September 2014, under the brand name of CANAGLU®.
MP-513 (teneligliptin)	MP-513 selectively inhibits DPP-4, thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. It was launched in Japan for the treatment of type2 diabetes mellitus in September 2012, under the brand name of TENELIA®.
MCI-186 (edaravone)	MCI-186 is a free radical scavenger. In Japan, it was launched under the brand name of Radicut® for the treatment of the acute stage of cerebral infarction in 2001, followed by Inhibition on progression of functional disorder in patients with Amyotrophic Lateral Sclerosis (ALS) in June, 2015.
MT-2412 (teneligliptin, canagliflozin)	MT-2412 is a fixed-dose combination of Teneligliptin(DPP-4 inhibitor) and Canagliflozin(SGLT2 inhibitor).
MP-214 (cariprazine)	MP-214 is a dopamine D3/D2 receptor partial agonist, licensed from Gedeon Richter (Hungary). Efficacy on negative symptoms and cognitive functions in addition to positive symptoms for schizophrenia is expected.
MT-4666 (encenicline)	MT-4666, licensed from FORUM Pharmaceuticals(US), is an α 7nACh receptor agonist, which ameliorates cognitive dysfunction by activation of both the cholinergic system and the glutamatergic system.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist, which shows renoprotective effect on diabetic nephropathy.
MT-1303 (amiselimod)	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist, which keeps lymphocytes sequestered in the lymph nodes and prevents them from contributing to autoimmune reactions. It's a successor of Imusera/Gilenya.
MT-2301	MT-2301 is a Haemophilus influenzae type b (Hib) vaccine, licensed from Nuron Biotech(US).
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of H5N1 influenza.
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of seasonal influenza.
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of H7N9 influenza.

(2) Additional Indications

Product name(Generic name)	Information
Remicade (infliximab)	Remicade is an anti-human TNF α monoclonal antibody. In Japan, it was launched as a treatment for Crohn's disease in 2002, followed by rheumatoid arthritis, intractable uveoretinitis caused by Behcet's disease, psoriasis, ankylosing spondylitis, ulcerative colitis, and entero-, neuro-, vasculo-Behcet's disease.
Tribik (Adsorbed diphtheria-purified pertussis-tetanus combined vaccine)	Tribik is a diphtheria-purified pertussis-tetanus combined vaccine. It has been jointly developed with the Research Foundation for Microbial Diseases of Osaka University.
Telavic (telaprevir)	Telavic was launched in Japan for the treatment of chronic hepatitis C (genotype1) in 2011, followed by Chronic hepatitis C (genotype2) in September, 2014.
Imusera (fingolimod)	Imusera is a sphingosine-1-phosphate receptor functional antagonist, which keeps lymphocytes sequestered in the lymph nodes and prevents them from attacking the myelin of the nerve cells in multiple sclerosis. It was launched as a treatment for multiple sclerosis in 2011 in Japan. Imusera had been jointly developed with Novartis Pharma for the domestic market. Global Phase 3 study for chronic inflammatory demyelinating polyradiculoneuropathy is underway. It has been jointly developed with Novartis Pharma for the domestic market.
CANAGLU (canagliflozin)	As a selective SGLT2 inhibitor, CANAGLU decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. It was launched in Japan for the treatment of type2 diabetes mellitus in September, 2014. It was launched for the treatment of type2 diabetes mellitus under the brand name of INVOKANA® by Janssen Pharmaceuticals, Inc. in the US and its affiliate in Europe.

(3) Licensing-out

Development code (Generic name)	Information
TA-7284 (canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. It was launched for the treatment of type2 diabetes mellitus under the brand name of INVOKANA® by Janssen Pharmaceuticals, Inc. in the US and its affiliate in Europe. The fixed dose combination with metformin (IR) was approved in Europe (April, 2014) and the US (August, 2014).
FTY720 (fingolimod)	Sphingosine-1-phosphate receptor functional antagonist. It was launched as a treatment for multiple sclerosis under the brandname of Imusera by Mitsubishi Tanabe Pharma in Japan. It is also marketed under the brand name of Gilenya by Novartis.
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscles.
MT-210	MT-210 is a 5-HT2A/ Sigma 2 receptor antagonist.
TA-7906	TA-7906 is a PDE4 inhibitor.
MCC-847 (masilukast)	MCC-847 is a Leukotriene D4 receptor antagonist.
MT-4580	MT-4580 is a Ca sensing receptor agonist.
Wf-516	Wf-516 acts through multiple mechanisms on several receptors* associated with the control of mood. *SSRI, 5-HT1A, dopamine transporter, and alpha-1A and B
Y-803	Y-803 is a Bromodomain inhibitor.

7 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of 1H FY2015	End of FY2014	Increase (Decrease)	Notes
Consolidated subsidiaries	27	28	(1)	Decrease: Tanabe U.S.A., Inc.
Non-consolidated subsidiaries	-	1	(1)	Decrease: Tanabe Seiyaku (Malaysia) Sdn. Bhd.
Affiliated companies	1	1	-	
Total	28	30	(2)	

(2) Consolidated Subsidiaries

[As of September 30, 2015]

	Company Name	Paid-in Capital	% Voting Control [% Indirect Ownership]	Settling Day	Description of Business
1	Yoshitomiyakuhin Corporation	JPY 385 million	100.0 [-]	End of Mar.	Provision of information about pharmaceuticals
2	Bipha Corporation	JPY 100 million	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
3	Mitsubishi Tanabe Pharma Factory Ltd.	JPY 1,130 million	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
4	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	JPY 400 million	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
5	Tanabe Seiyaku Hanbai, Ltd.	JPY 169 million	100.0 [-]	End of Mar.	Sale of generic pharmaceuticals, etc.
6	Tanabe R&D Service Co., Ltd.	JPY 44 million	100.0 [-]	End of Mar.	Support of R&D regarding pharmaceuticals
7	Tanabe Total Service Co., Ltd.	JPY 90 million	100.0 [-]	End of Mar.	Real estate management and creation of promotion materials, etc.
8	Mitsubishi Tanabe Pharma Holdings America, Inc.	USD 167	100.0 [-]	End of Mar.	Management of group companies in US
9	Mitsubishi Tanabe Pharma Development America, Inc.	USD 200	100.0 [100.0]	End of Mar.	R&D of pharmaceuticals
10	MP Healthcare Venture Management, Inc.	USD 100	100.0 [100.0]	End of Mar.	Investments in bio-ventures
11	Tanabe Research Laboratories U.S.A., Inc.	USD 3,000,000	100.0 [100.0]	End of Mar.	R&D of pharmaceuticals
12	MTPC Holdings Canada Inc.	CAD 267 million	100.0 [-]	End of Mar.	Investments in Medicago Group
13	Medicago Inc.	CAD 295 million	60.0 [56.2]	End of Mar.	Manufacture and sale of vaccines
14	Medicago USA Inc.	USD 99	60.0 [60.0]	End of Mar.	Manufacture of vaccines
15	Medicago R&D Inc.	CAD 500	60.0 [60.0]	End of Mar.	R&D of vaccines
16	Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd.	USD 1,000,000	100.0 [-]	End of Dec.	R&D of pharmaceuticals
17	Tianjin Tanabe Seiyaku Co., Ltd.	USD 16,230,000	75.4 [-]	End of Dec.	Manufacture and sale of pharmaceuticals
18	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0 [-]	End of Dec.	Sale of pharmaceuticals
19	Taiwan Tanabe Seiyaku Co., Ltd.	TWD 90,000,000	65.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
20	Tai Tien Pharmaceuticals Co., Ltd.	TWD 20,000,000	65.0 [-]	End of Mar.	Sale of pharmaceuticals
21	P.T. Tanabe Indonesia	USD 2,500,000	99.6 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
22	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KRW 2,100,000,000	100.0 [-]	End of Mar.	Manufacture and sale of pharmaceuticals
23	Mitsubishi Tanabe Pharma Europe Ltd.	GBP 4,632,000	100.0 [-]	End of Mar.	R&D of pharmaceuticals
24	Mitsubishi Tanabe Pharma GmbH	EUR 25,000	100.0 [100.0]	End of Mar.	Sale of pharmaceuticals

Note: Aside from the companies mentioned above, there are four consolidated companies under the liquidations.

(3) Affiliated Companies Accounted for by the Equity Method

[As of September 30, 2015]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]	Settling Day	Description of Business
1	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0 [-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	End of September, 2015	End of March, 2015
Issued	561,417,916	561,417,916
The company's own shares at the end of the period	428,692	428,340
Number of shares outstanding at the end of the period	560,989,224	560,989,576
Average number of the company's own share in the period	428,530	427,456
Average number of shares outstanding in the period	560,989,386	560,990,460

(2) Status of Major Shareholders

Rank	Name of Shareholders	End of September, 2015		End of March, 2015		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	The Master Trust of Japan, Ltd.	26,077	4.64%	2	24,137	4.30%
3	Nippon Life Insurance Company	12,065	2.15%	3	12,065	2.15%
4	Japan Trustee Services Bank, Ltd.	9,906	1.76%	4	10,669	1.90%
5	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	5	7,254	1.29%
6	STATE STREET BANK AND TRUST COMPANY 505225	5,685	1.01%	6	5,488	0.98%
7	Japan Trustee Services Bank, Ltd. (Trust Account 9)	4,932	0.88%	12	3,449	0.61%
8	Employee Stock Ownership Plan	4,317	0.77%	7	4,505	0.80%
9	STATE STREET BANK WEST CLIENT-TREATY 505234	4,311	0.77%	10	3,635	0.65%
10	Nipro Corporation	3,821	0.68%	9	3,821	0.68%

(3) Ownership and Distribution of Shares

	End of September, 2015			End of March, 2015		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial institutions	76	100,523	17.91%	75	98,321	17.52%
Foreign corporations and others	481	99,290	17.69%	465	100,650	17.93%
Individuals and others	14,023	23,752	4.23%	13,972	24,578	4.38%
Other corporations	240	334,404	59.58%	251	334,680	59.62%
Securities firms	35	3,344	0.60%	34	3,083	0.55%
Total	14,855	561,315	100.00%	14,797	561,315	100.00%
Less than trading unit	-	102	-	-	102	-

* The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stocks (428 thousands shares at the end of September, 2015 and 428 thousands shares at the end of March, 2015)

(4) Trend of Dividend and Stock Price

	FY2011	FY2012	FY2013	FY2014	1H FY2015	FY2015 Estimate
Dividends per share (yen)	35	40	40	42	22	44
Dividend payout ratio(%)	50.3	53.6	49.4	59.6	-	53.7
[prior to amortization of goodwill]	40.0	43.2	40.5	47.6	-	44.1
Stock price at the end of FY	1,161	1,445	1,443	2,062	2,105	-
Market capitalization (billion yen)	6,518	8,112	8,101	11,576	11,818	-

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNF α monoclonal antibody
<p>Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for eight weeks with a single administration. It has indications for the treatment of rheumatoid arthritis, Crohn's disease, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis. In addition, in July 2009 and August 2011, changes in usage/dosage were approved for rheumatoid arthritis, and Crohn's disease, respectively.</p> <p>Entero-Behcet's disease, neuro-Behcet's disease, and vasculo-Behcet's disease in cases where existing treatment is inadequate were approved in August, 2015.</p> <p>It was designated as an orphan drug of refractory Kawasaki disease, and filed for Kawasaki disease in May, 2015.</p> <p>Partial change in dosage and usage (increased dose) for psoriasis was filed in July, 2015.</p> <p>Origin: Janssen Biotech</p>			
Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders
<p>Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets, was approved in March and launched in July 2007. Pediatric indications (from seven to fifteen years old) was approved in May, 2015.</p> <p>Origin: Ube Industries</p>			
Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration
<p>Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist, developed by Tanabe, is the world's first oral TRH derivative drug. An additional formulation, orally disintegrating tablets, was launched in October 2009.</p>			
Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β 1 antagonist (Treatment of hypertension, angina pectoris, and arrhythmias, chronic heart failure)
<p>Maintate is a representative β-blocker used in more than 100 countries around the world. It exhibits high selectivity for β 1 receptor and excellent pharmacokinetics profiles. It has high efficacy and safety, and evidence-based cardioprotective action. In addition to the indication of chronic heart failure which was approved in May, 2011, the indication of atrial fibrillation has been newly approved in June, 2013 . Maintate is the only β-blocker with both indications of chronic heart failure and atrial fibrillation in Japan.</p> <p>Origin: Merck Serono (Germany)</p>			
Simponi (Golimumab)	Launch: Sep. 2011	Category	Anti-TNF α monoclonal antibody
<p>Simponi is a human anti-TNFα monoclonal antibody for the treatment of rheumatoid arthritis (including prevention of articular structural damage), and co-marketed with Janssen Pharmaceutical. It shows a long acting efficacy by subcutaneous injection once every four weeks, and currently is under development for the ulcerative colitis by Janssen Pharmaceutical.</p> <p>Origin: Janssen Biotech</p>			
Tenelia (Teneligliptin)	Launch: Sep. 2012	Category	Selective DPP-IV inhibitor
<p>Tenelia, which Mitsubishi Tanabe has created and developed, is the first DPP-4 inhibitor originating in Japan that has ever been launched. It inhibits the function of dipeptidyl peptidase-4 (DPP-4), which selectively breaks down glucagon-like peptide-1(GLP-1), a hormone secreted from the gastrointestinal tract in response to food intake. In this way, Tenelia promotes insulin secretion and suppresses glucagon secretion, thereby demonstrating blood glucose lowering action.</p>			
Lexapro (Escitalopram)	Launch: Aug. 2011	Category	Selective serotonin reuptake inhibitor (SSRI)
<p>Lexapro, a highly selective serotonin reuptake inhibitor (SSRI), has been globally approved in 98 countries and regions. It shows good efficacy and tolerability in patients with depressive disorder. Moreover, due to simple dosage and administration, it is expected to improve adherence of the treatment.</p> <p>Social anxiety disorder (SAD) was filed in November, 2014.</p> <p>Origin: H. Lundbeck A/S (Denmark), Manufacturer and distributor: Mochida Pharmaceutical Co., Ltd</p>			
Kremezin	Launch: Apr. 2011	Category	Agent for treatment of Chronic renal failure
<p>Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April, 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC.</p> <p>Origin, Manufacturer and distributor: Kureha</p>			

Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions
Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in the human body. Urso has effects of hepatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.			
Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent
Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.			
Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT ₂ blocker (Anti-platelet agent)
Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as ulcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of collateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels.			
Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)
Radicut is the world's first brain protecting agent (free radical scavenger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administered for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was launched in May 2010. It was designated as an orphan drug of amyotrophic lateral sclerosis (ALS) and approved for ALS in June, 2015.			
TETRABIK (Absorbed Diphtheria-purified Pertussis-tetanus inactivated polio)	Launch: Oct. 31. 2012	Category	Prevention of diphtheria, pertussis, tetanus and polio
TETRABIK is a combined vaccine that prevents acute poliomyelitis (polio), pertussis, diphtheria and tetanus. It is used at 1st term (initial 3 times) and 1st term (additional 1 time), in total 4 times, of the regular vaccination. By using TETRABIK, It is expected to avoid the very rare occurrence of paralytic symptoms similar to those in natural polio due to live-attenuated oral polio vaccine. Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)			

News Releases

The major news releases after April, 2015 are as follows.

Please refer to the Company's website for the details. (<http://www.mt-pharma.co.jp/e/release/index.php>)

Date	Contents
April 1, 2015	Execution of License Agreement on VMAT2 Inhibitor NBI-98854
May 22, 2015	Mitsubishi Tanabe Pharma provides Compound Library to Screening Program of Global Health Innovative Technology Fund
May 26, 2015	Approval for Additional Pediatric Indications in Japan Received for TALION Tablets and TALION OD Tablets, Anti-Allergic Agents
June 26, 2015	RADICUT inj. 30mg and RADICUT BAG for I.V. Infusion 30mg Mitsubishi Tanabe Pharma Corporation receives approval for additional indication for Amyotrophic Lateral Sclerosis (ALS) in Japan
July 10, 2015	Application Filed for a Partial Change in Dosage and Usage of REMICADE for I.V. Infusion 100, an Anti-Human TNF α Monoclonal Antibody, in Psoriasis
August 24, 2015	Approval of REMICADE for I.V. Infusion 100, an Anti-Human TNF α Monoclonal Antibody, for Additional Indications for Entero-Behcet's Disease, Neuro-Behcet's Disease, and Vasculo-Behcet's Disease
September 9, 2015	Biogen and Mitsubishi Tanabe Pharma Conclude a License Agreement on MT-1303, a Therapeutic Agent for Autoimmune Diseases
September 15, 2015	MT-4666 in Alzheimer's Disease Discontinuation of Global Phase 3 Clinical Trial Program in Japan
September 17, 2015	Notice Regarding Worldwide Patent and Know-how Transfer, Excluding Japan and Certain Other Territories in Asia, for TA-8995 (CETP inhibitor), a Treatment Agent for Dyslipidemia
September 24, 2015	MedImmune and Tanabe Research Laboratories / Mitsubishi Tanabe Pharma Enter into Strategic Collaboration and Licensing Agreement for the Development of Pyrrolbenzodiazepine (PBD)-Based Antibody Drug Conjugates to Treat Cancer
October 2, 2015	Mitsubishi Tanabe Pharma and Regeneron Conclude Collaboration Agreement for Fasinumab, NGF Antibody



Mitsubishi Tanabe Pharma